Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Natera, Inc. trades on Nasdaq under the ticker NTRA. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks NTRA has traded between 167.99 $ and 437.41 $. As of 09 October 2026 the price stood 86.38 % of the way from the 52-week low to the high.
Over one year NTRA shares rose 132.85 %; over six months they rose 107.59 %. Volatility over 90 days is 50.98 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 22.2, above the sector median of 3.9. Price to book is 31.3, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 392.90 | 407.06 | 391.51 | 400.71 | 1M |
| 08 October 2026 | 387.59 | 392.96 | 380.39 | 390.79 | 2M |
| 07 October 2026 | 393.02 | 401.09 | 383.45 | 395.56 | 3M |
| 06 October 2026 | 429.01 | 437.41 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Natera makes genetic tests — from prenatal screening to monitoring residual cancer.
The original line is non-invasive prenatal testing from maternal blood, now routine practice. The same technology produced a second and more valuable one: analysing residual tumour DNA in blood after surgery, showing whether the disease will return before a scan can.
The economics depend not on the science but on reimbursement: until an insurer covers the test, the laboratory performs it at near-loss. Each coverage decision therefore changes the outlook more than clinical data does. Test cost falls with volume, so the path to profitability depends on laboratory utilisation as much as on price. The company grows quickly and pays no dividend.
Address:13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753, US
Natera, Inc. reported revenue of 2.5B $ and a net loss of 226M $ over the last four quarters. Net margin is −9.05 %. Revenue changed by +36.59 % year over year. Earnings per share are −1.62 $. Market capitalisation is 55.6B $.
NTRA has a return on equity of −12.76 %, above the sector median of −41.68 %. Return on assets is −8.66 %, above the sector median of −32.11 %. Operating margin is −12.97 %, above the sector median of −26.84 %.
| 145M |
| GRALGRAIL, Inc. | 141.86 | +6.98 % | 138M |
| CELCCelcuity Inc. | 67.68 | −0.28 % | 90M |
| CDNACareDx, Inc. | 63.71 | +2.42 % | 80M |
| BLLNBillionToOne, Inc. | 98.28 | +3.01 % | 66M |
| 394.77 |
| 400.65 |
| 2M |
| 05 October 2026 | 410.32 | 427.18 | 405.24 | 425.64 | 2M |
| 02 October 2026 | 409.40 | 413.36 | 401.00 | 410.35 | 2M |
| 01 October 2026 | 413.31 | 423.43 | 407.37 | 408.47 | 2M |
| 30 September 2026 | 416.02 | 427.47 | 413.29 | 413.31 | 2M |
| 29 September 2026 | 413.69 | 421.64 | 409.25 | 414.52 | 2M |
| 28 September 2026 | 409.02 | 417.38 | 406.30 | 411.77 | 2M |
| 25 September 2026 | 410.00 | 415.75 | 407.48 | 412.56 | 2M |
| 24 September 2026 | 390.52 | 412.93 | 388.47 | 408.79 | 2M |
| 23 September 2026 | 386.94 | 394.86 | 384.96 | 390.79 | 2M |
| 22 September 2026 | 368.26 | 391.93 | 365.20 | 390.90 | 2M |
| 21 September 2026 | 371.92 | 373.07 | 363.96 | 370.64 | 2M |
| 18 September 2026 | 365.78 | 369.69 | 358.90 | 369.39 | 4M |
| 17 September 2026 | 350.50 | 366.70 | 348.26 | 366.31 | 3M |
| 16 September 2026 | 350.18 | 357.15 | 343.28 | 345.34 | 1M |
| 15 September 2026 | 340.34 | 351.78 | 338.82 | 350.78 | 2M |
| 14 September 2026 | 327.91 | 343.00 | 327.15 | 341.79 | 1M |